Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

7.400 +0.210 (+2.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Silence (SLN) Q2 Revenue Drops 71%
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
 
Via Benzinga
Earnings Scheduled For February 27, 2025
 
Via Benzinga
Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)
 
Via Benzinga
The Analyst Landscape: 6 Takes On Silence Therapeutics
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
These stocks are moving in today's pre-market session
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025. 
Via Talk Markets
Topics Stocks / Equities
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Analyst Scoreboard: 4 Ratings For Silence Therapeutics
 
Via Benzinga
Analyst Expectations For Silence Therapeutics's Future
 
Via Benzinga
The Analyst Landscape: 6 Takes On Silence Therapeutics
 
Via Benzinga
Top 3 Health Care Stocks That May Explode In Q4
 
Via Benzinga
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges. 
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing In Q4
 
Via Benzinga
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
Silence Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in August 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. 
Via InvestorPlace
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
What 7 Analyst Ratings Have To Say About Silence Therapeutics
 
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Silence Therapeutics
 
Via Benzinga
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
Silence Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one. 
Via InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday. 
Via Benzinga
What's Going On With Silence Therapeutics Stock Today?
Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of... 
Via Benzinga
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.